Literature DB >> 16096715

Exercise maintains bone density at spine and hip EFOPS: a 3-year longitudinal study in early postmenopausal women.

K Engelke1, W Kemmler, D Lauber, C Beeskow, R Pintag, W A Kalender.   

Abstract

It is an important aim in the prevention of osteoporosis to stop or decelerate bone loss during the early postmenopausal years. Here we report on results of the 3-year EFOPS exercise trial in osteopenic women. The exercise strategy emphasized low-volume high-resistance strength training and high-impact aerobics. Forty-eight fully compliant women (55.1+/-3.3 years) with no medication or illness affecting bone metabolism participated in the exercise group (EG); 30 women (55.5+/-3.0 years) served as non-training controls (CG). At baseline there were no significant between-group differences with respect to physical fitness, bone mineral density, pain and nutritional status. The training consisted of two group training and two home training sessions per week. The study participants of both groups were individually supplemented with calcium and vitamin D (cholecalciferol). Bone mineral density (BMD) was measured by DXA at the lumbar spine, proximal femur and distal forearm and by QCT at the lumbar spine. Speed of sound and broadband ultrasound attenuation were determined at the calcaneus by quantitative ultrasound (QUS). Pain frequency and intensity at different skeletal sites were assessed via questionnaire. After 38 months, the following within-group changes were measured: DXA lumbar spine, EG: 0.8% n.s.; CG: -3.3% P<0.001; QCT trabecular ROI, EG: 1.1% n.s; CG: -7.7% P<0.001; QCT cortical ROI, EG: 5.3% P<0.001; CG: -2.6% P<0.001; DXA total hip: EG: -0.2% n.s; CG -1.9%, P<0.001; DXA distal forearm, EG: -2.8% P<0.001; CG: -3.8% P<0.001; BUA, EG: -0.3% n.s; CG -5.4% P<0.001; SOS, EG: 0.3% n.s; CG -1.0% P<0.001. At year 3 between-group differences relative to the exercise group were: DXA lumbar spine: 4.1% P<0.001; QCT trabecular ROI: 8.8% P<0.001; QCT cortical ROI: 7.9% P<0.001; DXA total hip: 2.1%, P<0.001; DXA distal forearm: 1.0% n.s.; BUA: 5.8% P<0.05; SOS: 1.3% P<0.001. Pain frequency and intensity in the spine significantly decreased in the exercise group and increased in the control group, while no between-group differences were detected in the main joints. In summary, over a period of 3 years our low-volume/high-intensity exercise program was successful to maintain bone mineral density at the spine, hip and calcaneus, but not at the forearm.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096715     DOI: 10.1007/s00198-005-1938-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  45 in total

Review 1.  Exercise at menopause: a critical difference.

Authors:  M Burghardt
Journal:  Medscape Womens Health       Date:  1999 Jan-Feb

Review 2.  Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women.

Authors:  B A Wallace; R G Cumming
Journal:  Calcif Tissue Int       Date:  2000-07       Impact factor: 4.333

Review 3.  The role of changes in mechanical usage set points in the pathogenesis of osteoporosis.

Authors:  H M Frost
Journal:  J Bone Miner Res       Date:  1992-03       Impact factor: 6.741

Review 4.  Homeostatic control of bone structure: an application of feedback theory.

Authors:  C H Turner
Journal:  Bone       Date:  1991       Impact factor: 4.398

5.  Controlled trial of weight bearing exercise in older women in relation to bone density and falls.

Authors:  M E McMurdo; P A Mole; C R Paterson
Journal:  BMJ       Date:  1997-02-22

6.  HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.

Authors:  J Heikkinen; E Kyllönen; E Kurttila-Matero; G Wilén-Rosenqvist; K S Lankinen; H Rita; H K Väänänen
Journal:  Maturitas       Date:  1997-03       Impact factor: 4.342

7.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

8.  Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women.

Authors:  S Cheng; S Sipilä; D R Taaffe; J Puolakka; H Suominen
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

9.  Effects of skeletal loading on bone mass and compensation mechanism in bone: a new insight into the "mechanostat" theory.

Authors:  Toshihiro Sugiyama; Akira Yamaguchi; Shinya Kawai
Journal:  J Bone Miner Metab       Date:  2002       Impact factor: 2.626

10.  The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study.

Authors:  N C Lee; G L Rubin; R Borucki
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

View more
  39 in total

Review 1.  Exercise for the prevention of osteoporosis in postmenopausal women: an evidence-based guide to the optimal prescription.

Authors:  Robin M Daly; Jack Dalla Via; Rachel L Duckham; Steve F Fraser; Eva Wulff Helge
Journal:  Braz J Phys Ther       Date:  2018-11-22       Impact factor: 3.377

2.  Differential effects of strength versus power training on bone mineral density in postmenopausal women: a 2-year longitudinal study.

Authors:  Simon von Stengel; Wolfgang Kemmler; Willi A Kalender; Klaus Engelke; Dirk Lauber
Journal:  Br J Sports Med       Date:  2007-06-05       Impact factor: 13.800

3.  The effect of moderate impact exercise on skeletal integrity in master athletes.

Authors:  N F Velez; A Zhang; B Stone; S Perera; M Miller; S L Greenspan
Journal:  Osteoporos Int       Date:  2008-03-20       Impact factor: 4.507

Review 4.  Bone health and back pain: what do we know and where should we go?

Authors:  A M Briggs; L M Straker; J D Wark
Journal:  Osteoporos Int       Date:  2008-08-21       Impact factor: 4.507

5.  The effects of differing resistance training modes on the preservation of bone mineral density in postmenopausal women: a meta-analysis.

Authors:  R Zhao; M Zhao; Z Xu
Journal:  Osteoporos Int       Date:  2015-01-21       Impact factor: 4.507

6.  The Lifestyle History: A Neglected But Essential Component of the Medical History.

Authors:  Robyn L Houlden; Hope H Yen; Arash Mirrahimi
Journal:  Am J Lifestyle Med       Date:  2017-04-11

7.  The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women.

Authors:  Linda Denise Fernandes Moreira; Fernanda Cerveira A O Fronza; Rodrigo Nolasco Dos Santos; Patrícia Lins Zach; Ilda S Kunii; Lilian Fukusima Hayashi; Luzimar Raimundo Teixeira; Luis Fernando Martins Kruel; Marise Lazaretti Castro
Journal:  J Bone Miner Metab       Date:  2013-09-19       Impact factor: 2.626

8.  Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial.

Authors:  S Kukuljan; C A Nowson; S L Bass; K Sanders; G C Nicholson; M J Seibel; J Salmon; R M Daly
Journal:  Osteoporos Int       Date:  2008-10-28       Impact factor: 4.507

9.  Lower body negative pressure treadmill exercise as a countermeasure for bed rest-induced bone loss in female identical twins.

Authors:  Sara R Zwart; Alan R Hargens; Stuart M C Lee; Brandon R Macias; Donald E Watenpaugh; Kevin Tse; Scott M Smith
Journal:  Bone       Date:  2006-10-27       Impact factor: 4.398

10.  The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity.

Authors:  Nicolas Bonnet; Kara N Standley; Estelle N Bianchi; Vincent Stadelmann; Michelangelo Foti; Simon J Conway; Serge L Ferrari
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.